comparemela.com

Latest Breaking News On - Elderly relapsed - Page 1 : comparemela.com

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

United statesAstellas pharmaMatthew beckActinium pharmaceuticals incInvestor relations communicationsExchange commissionActimaba national cancer instituteOncology lg chem life sciencesSociety of hematologic oncologyActinium pharmaceuticalsHematologic oncologyRandomized phaseElderly relapsedPatients with activeFailed targetedGrand ballroom

Actinium Pharma to Present at the Maxim Healthcare Virtual Conference

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Matthew beckInvestor relations communicationsActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incMaxim healthcare virtual conferenceActinium pharmaceuticalsElderly relapsedRefractory acute myeloid leukemiaComplete remission

Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Matthew beckInvestor relations communicationsActinium pharmaceuticals incActinium pharmaceuticalsRadiopharmaceutical innovation summitElderly relapsedRefractory acute myeloid leukemiaComplete remission

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,.

Matthew beckSandesh sethBoglarka gyurkoczaInvestor relations communicationsExchange commissionEuropean hematology associationPrnewswire actinium pharmaceuticals incActinium pharmaceuticals incChief executiveElderly relapsedRefractory acute myeloid leukemiaComplete remission

Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Matthew beckExchange commissionActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incEuropean hematology associationInvestor relations communicationsElderly relapsedRefractory acute myeloid leukemiaComplete remissionActinium pharmaceuticals

vimarsana © 2020. All Rights Reserved.